A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- UCB Biopharma SRL
- ID
- NCT05681715
- Phase
- Phase 3 Myasthenia Gravis Research Study
- Study Type
- Interventional
- Participants
- Expecting 30 study participants
- Last Updated